IGC Pharma, a clinical-stage biopharmaceutical company, reported fiscal year 2025 revenue of $869,000 with a net loss improved to $4.15 million. Its core development effort centers on the Phase 2 CALMA trial for Alzheimer’s agitation. Recent debt financings aim to bolster working capital, though the current ratio under one signals sustained liquidity pressure. Management’s consideration of digital assets for treasury diversification introduces novel risks uncommon in early-stage pharma firms. Continuous monitoring of clinical milestones and financing needs will be critical in assessing its path forward.